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http://www.biomedcentral.com/1471-2407/14/562RESEARCH ARTICLE Open Access3'-Ethynylcytidine, an RNA polymerase inhibitor,
combined with cisplatin exhibits a potent
synergistic growth-inhibitory effect via Vaults
dysfunction
Hiroto Fukushima, Tetsuya Abe, Kazuki Sakamoto, Hiroaki Tsujimoto, Shinji Mizuarai and Shinji Oie*Abstract
Background: We previously reported that 3'-ethynylcytidine (ECyd, TAS-106), an RNA polymerases inhibitor,
enhances the anti-tumor efficacy of platinum in several tumor types in both in vitro and in vivo tumor models.
However, the molecular mechanisms underlying the ECyd-induced enhancement remain elusive.
Methods: Cisplatin (CDDP)-resistant head and neck cancer KB cells were established by stepwise dose
escalation with CDDP. The combination effect of ECyd and CDDP were assessed using isobologram analysis.
The transcriptional and post-translational statuses of several molecules were detected using real-time PCR,
immunoblot analysis and immunocytochemistry. Xenograft assays were used to confirm the mechanisms
underlying the ECyd induced enhancement of CDDP anti-tumor efficacy in vivo.
Results: ECyd sensitized KB to CDDP by inhibiting the drug transporter Vault complex (Vaults). First, we showed
that Vaults were overexpressed in CDDP-resistant KB cells. The suppression of major vault protein (MVP) by RNA
interference restored the sensitivity to CDDP. Next, we showed that ECyd significantly sensitized the resistant
cells to CDDP, compared with the parental paired cell line. A molecular analysis revealed that ECyd inhibited the
synthesis of vRNAs as well as the induction of MVP, both of which are critical components of Vaults as a drug
transporter. Furthermore, we found that the synergistic effect of ECyd and CDDP was correlated with the MVP
expression level when the effect was analyzed in additional cancer cell lines. Finally, we demonstrated that ECyd
decreased the vRNAs expression level in xenograft tumor.
Conclusions: Our data indicated the ability of ECyd to cancel the resistance of cancer cells to CDDP by inhibiting the
Vaults function and the decrease of Vaults expression itself, and the ability of the combination therapy with CDDP and
ECyd to offer a new strategy for overcoming platinum resistance. Moreover, the study results suggest that Vaults could
be a biomarker for stratifying patients who may benefit from the combination therapy with ECyd and platinum.
Keywords: ECyd, Vaults, Cisplatin, Biomarker, ResistanceBackground
1-(3-C-Ethynyl-s-D-ribo-pentofuranosyl)cytosine (3'-ethy-
nylcytidine, ECyd, TAS-106) (Additional file 1: Figure
S1A) is an antitumor cytidine analogue possessing potent
cytotoxic and antitumor activities in preclinical thera-
peutic models via the inhibition of RNA biosynthesis
through the competitive inhibition of RNA polymerase I,* Correspondence: ohiesinj@taiho.co.jp
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article, unless otherwise stated.II and III. When administered, ECyd is initially phosphor-
ylated by uridine-cytidine kinase (UCK) 1 or 2, generating
3'-ethynylcytidine-5'-monophosphate (ECMP). ECMP then
undergoes two additional phosphorylations, generating 3'-
ethynylcytidine-5'-diphosphate (ECDP) and 3'-ethynylcyti-
dine-5'-triphosphate (ECTP), respectively [1]. ECTP is the
final active moiety that inhibits RNA polymerases and ex-
erts the anti-tumor effect (Additional file 1: Figure S1B).
Among the three phosphorylation steps, UCKs that
mediate the initial phosphorylation are the rate limitingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in cancer cells [3], while UCK1 expression is observed in
both cancer and normal cells, explaining the greater anti-
tumor effect on cancer cells while sparing normal cells
[4-6]. Furthermore, ECyd is a more efficient substrate for
UCK2 than for UCK1. In addition, the expression level of
not UCK1 but UCK2 is closely correlated with cellular
sensitivity to ECyd [6].
Previously, we reported that the combination of ECyd
and CDDP showed potent anti-proliferative effects in
several in vitro cancer cell lines and an in vivo xenograft
tumor model [7]. Given the remarkable synergistic effect
of ECyd and CDDP, we have initiated a Phase I clinical
trial combining ECyd and platinum for patients with
solid tumors. This novel combination therapy might
provide great benefit for patients whose tumor has an
intrinsic resistance to CDDP or an acquired resistance
after CDDP treatment.
Head and neck (H&N) cancer is the sixth most common
cancer worldwide, and around 90% of cases have an epi-
thelial origin that presents as squamous cell carcinoma
(SCCHN). Therefore, this histopathological subtype forms
the main focus of H&N cancer treatment [8]. CDDP is
one of the most effective antitumor agents for the treat-
ment of patients with SCCHN. However, acquired resist-
ance to CDDP is a major obstacle to effective, potentially
curative chemotherapy in the clinical management of such
patients. Even with new second-line options, including
Erbitux, a great need remains for alternatives that can de-
liver improved survival rates in metastatic disease settings.
Effective new agents with different targets and/or
mechanisms of action are highly needed as either first- or
second-line treatments, in combination with standard
chemotherapy or as a monotherapy, especially for meta-
static SCCHN [9].
The molecular mechanisms underlying the resistance
to CDDP remain unknown in human SCCHN cancers
[10]. Several mechanisms found in many drug-resistant
cancer cells include a reduction of drug uptake, an increase
in drug export, an increase in intracellular detoxification,
an increase in DNA repair systems, and so on. With respect
to CDDP drug resistance, multidrug resistance-associated
protein 2 (MRP2) might be correlated with CDDP resist-
ance [11]. However, in general, multiple reports have
shown that CDDP is not a substrate for P-glycoprotein,
the product of the multidrug resistance gene MDR, and
other members of the ATP-binding cassette superfamily
of transporters (ABC transporters). Thus, more detailed
studies are required to decipher the mechanism of CDDP
drug resistance.
Recently, Vault complex (Vaults) was reported to be
associated with CDDP resistance through the elimination
of platinum chemotherapeutics from cancer cells [12-16].
Vaults are barrel-shaped cytoplasmic ribonucleoproteinparticles composed of multiple copies of three different
proteins and a small RNA [17]. The mammalian Vaults are
composed of major vault protein (MVP), vault poly ADP-
ribose polymerase (VPARP) and telomerase-associated
protein 1 (TEP-1), which are complexed with small un-
translated vault RNAs (vRNAs) [18-20]. Among the four
components, the major component of Vaults is MVP,
which constitutes more than 70% of the total mass. Vaults
were initially identified as clathrin-coated vesicles, and the
first evidence that these structures may contribute to drug
resistance was provided when lung resistance-related pro-
tein (LRP) was highly expressed in non-P-glycoprotein-
mediated drug-resistant cell lines [21]. Subsequent studies
showed that LRP is identical to human MVP [22]. Al-
though Vaults are expressed in all human tissues, elevated
levels of MVP are found in the gut epithelium, lung epi-
thelium, macrophages, and dendritic cells, which are all
typically exposed to xenobiotics [23-26]. These findings
imply that Vaults have a role in the defense of such tissues
against toxic insults. Consistent with this hypothesis,
MVP has been found to be overexpressed in various
multidrug-resistant cancer cell lines, together with a range
of clinical samples such as H&N, ovarian, lung carcinomas,
hepatoblastoma, acute myeloid leukemia, and multiple
myeloma [12,23,26]. An accumulating number of experi-
mental and clinical investigations have suggested that an
elevated expression at the time of diagnosis was an inde-
pendent prognostic factor for a poor response to chemo-
therapy and an adverse clinical outcome for a variety of
tumor types [16,27-29]. Because the hollow barrel-shaped
structure of the Vaults complex and its subcellular
localization have indicated that Vaults are involved in
xenobiotic transportation, it was postulated that Vaults
contribute to drug resistance by transporting drugs away
from their intracellular targets and/or the sequestration of
drugs [30,31]. Although the decisive function of the
vRNAs component is not clear, the vRNAs reportedly has
the ability to bind chemotherapeutics, suggesting a pivotal
role in drug export.
Here, we investigated the antitumor activity of ECyd
combined with CDDP in platinum-resistant SCCHN
cancer cells named KB/CDDP(T); we found that ECyd sup-
presses the expression of vRNAs and the CDDP-mediated
induction of Vaults, restoring sensitivity to CDDP.
Methods
Cells and reagents
KB cells, a human nasopharyngeal carcinoma cell line,
and A549 cells, a human lung carcinoma cell line, were
obtained from the American Type Culture Collection.
CDDP-resistant KB cells, KB/CDDP(T), were established
by stepwise dose escalation with CDDP in our laboratory.
ECyd was synthesized at Taiho Pharmaceutical Co., Ltd.
(Tokyo, Japan). CDDP and CBDCA were obtained from
Fukushima et al. BMC Cancer 2014, 14:562 Page 3 of 12
http://www.biomedcentral.com/1471-2407/14/562Nippon Kayaku Co., Ltd. (Tokyo, Japan), SN-38 was
obtained from Sigma-Aldrich Co., LLC. (Missouri, USA),
and ADM was obtained from Kyowa Hakkou Kirin Co.,
Ltd. (Tokyo, Japan).
Cell culture and cell survival analysis
KB and KB/CDDP(T) cells were grown in Eagle's
Minimum Essential medium containing 10% fetal bovine
serum, and A549 cells were grown in F-12 K Medium
containing 10% fetal bovine serum. SHIN-3 and HRA cells
were grown in RPMI-1640 Medium containing 10% fetal
bovine serum. The cells were incubated in a humidified
atmosphere of 5% CO2 at 37°C. A total of 1×10
3 cells in
100 μL of culture medium were inoculated into each well
of a 96-well plate. After 24 hours of incubation at 37°C,
100 μL of anticancer drugs diluted with the medium to
various concentrations were added to each well and
the cultures were incubated for 72 hours at 37°C in 5%
CO2. Cell viability was quantified using a colormetric
assay using a Cell Counting Kit-8 (Dojindo, Kumamoto,
Japan) [32].
Drug interaction analysis
A total of 5 x 102 cells in 100 μL of culture medium
were inoculated into each well of a 96-well plate. After
24 hours of incubation at 37°C, 50 μL each of ECyd
and CDDP diluted with the medium to various concen-
trations were added to each well; the cultures were then
incubated for 24 hours at 37°C in 5% CO2, followed
by washing each well twice with drug-free medium and
96 hours of incubation with drug-free medium. The
cell viability was quantified using a colormetric assay
using a Cell Counting Kit-8 (Dojindo) [32]. The presence
of an additive or synergistic interaction between CDDP
and ECyd was determined using the isobologram analysis
reported by Steel and Peckham [33]. The type of inter-
action between CDDP and ECyd was evaluated by com-
paring the cytotoxic effects obtained after simultaneous
exposures to the drugs with the effects observed after ex-
posure to CDDP or ECyd alone. The interaction indices
were calculated using the following equation: inter-
action index = CDDP c/CDDP e + ECyd c/ECyd e, where
CDDP e and ECyd e are the concentrations of CDDP
and ECyd that inhibit 50% of the proliferation when used
alone, and CDDP c and ECyd c are the concentrations
of CDDP and ECyd that produce the same effect
when used in combination. According to this method, an
interaction index of less than 1.0 indicates a synergistic
interaction between two drugs, an interaction index of
more than 1.0 indicates antagonism, and an index of 1.0
indicates an additive interaction. The data point in the
isobologram corresponds to the actual IC50 dose of the
combined CDDP and ECyd treatment. If a data point is
on or within the three lines, this represents an additivetreatment effect, whereas a data point that lies below or
above the three lines indicates synergism or antagonism,
respectively.
Preparation of total cell lysates and immunoblot analysis
Whole cell lysates were extracted with the M-PER
Mammalian Protein Extract (Pierce, Oregon, USA) con-
taining protease inhibitors. The protein concentrations
were determined using a bicinchoninic acid protein assay,
and equal amounts of protein were separated using a 7.5%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
were electroblotted onto polyvinylidene difluoride mem-
branes (Millipore, Massachusetts, USA). After blocking, the
membranes were probed with primary antibodies against
UCK2, MVP (Novus biologicals, Colorado, USA) and β-
actin (abcam, Cambridge, UK). After incubation with
horseradish peroxidase-conjugated secondary antibodies,
the antigen-antibody complexes were visualized using
enhanced chemiluminescence (Pierce). Images were
captured using an image analyzer (LAS 3000; Fuji Film,
Tokyo, Japan).
Immunocytochemistry
Cells plated on chamber slides were fixed with ice-cold
100% methanol, quenched with 0.3% H2O2, and blocked
with normal goat serum. After incubation for 30 min
with the primary antibodies, anti-MVP, and washing,
the biotinylated secondary antibodies were added for
30 min, washed, then followed by preformed avidin
DH-biotinylated horseradish peroxidase H complex for
30 min. Slides were then overlaid with DAB, rinsed,
dried, mounted, and cover-slipped.
RNA-mediated interference
Stealth RNA-mediated interference (RNAi; Invitrogen,
California, USA) for MVP or stealth RNAi negative
control (Invitrogen) was transfected using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s
protocol.
RNA isolation and quantitative real-time reverse-
transcription PCR quantification
RNAs were extracted using the RNeasy Mini kit (Qiagen,
Venlo, Netherlands). First-strand cDNAs were synthesized
using the Quantitect Reverse Transcription kit (Qiagen).
Gene expression levels were determined using either the
TaqMan Gene Expression Master Mix or the SYBR Green
PCR Master Mix on an ABI Prism 7900 platform (Applied
Biosystems, California, USA), according to the manufac-
turer’s protocol. 18S rRNA was used for normalization.
The relative quantification of the MVP mRNA and
vRNAs was calculated using a comparative cycle threshold
method [34].
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Tumor fragments approximately 2 mm3 in size were
transplanted subcutaneously into male BALB/cAJcl-nu
nude mice (CLEA Japan, Tokyo, Japan). After reaching a
tumor volume of ~150 mm3, the mice were randomly
assigned to a control group and drug treatment, each con-
sisting of six animals (day 0). CDDP (7 mg/kg) was admin-
istered by intravenous injection and ECyd (0.1 mg/kg/hr)
was continuously administered using osmotic pumps
(Alzet, California, USA) to six mice on day 1. Tumors
were excised at 6 hours post-administration. The animal
experiments were performed according to the guidelines
and with the approval of the Institutional Animal Care
and Use Committee of Taiho Pharmaceutical Co., Ltd.
The permitted experimental number is 09TC11.
Results
Establishment of platinum-resistant KB cells, KB/CDDP(T),
through exposure to increasing concentrations of CDDP
KB/CDDP(T) was established as a CDDP-resistant cell
line by exposing its parental head and neck cancer KB
cells to increasing concentrations of CDDP. We exam-
ined the sensitivities to several antitumor agents in both
KB/CDDP(T) and parental KB cells. A cytotoxicity and cell
viability assay showed a prominent resistance to CDDP
in KB/CDDP(T) cells, compared with its parental cells
(Figure 1A). The IC50 values for CDDP in KB and KB/
CDDP(T) cells were 0.82 and 6.92 μmol/L, respectively,
meaning that the KB/CDDP(T) cells were more than 8-fold
resistant to CDDP than the parental cells (Table 1). Before
examining the sensitizing effect of ECyd on the CDDP anti-
tumor effect in the resistant cells, we confirmed that the
KB and KB/CDDP(T) cells exhibited similar sensitivities to
ECyd alone (Figure 1B). We also confirmed that the protein
expression of UCK2, which is the rate-limiting enzyme re-
quired for ECyd activation to exert its anti-tumor effect,
was not changed in KB/CDDP(T) when analyzed using
immunoblot analysis (Figure 1C). Immunocytochemistry
(ICC) data also indicated no differences in expression
or subcellular localization between the two cell lines
(Figure 1D). We also assessed the sensitivity to other
anticancer drugs (carboplatin [CBDCA], Adriamycin
[ADM], and SN-38) between the parental and CDDP-
resistant cells. The IC50 values of both cells to the antican-
cer drugs are shown in Table 1. The KB/CDDP(T) cells
exhibited resistance not only to CDDP, but also to
CBDCA, ADM, and SN-38 without affecting the sensitiv-
ity to ECyd. All these agents are known to be substrates
for the Vaults to render resistance to these drugs.
Expression level of Vaults affects the sensitivity to CDDP
To elucidate the mechanism accounting for the drug-
resistance to CDDP, we investigated a ribonucleotide
protein, Vaults, since various reports have shown thatVaults expression significantly affects the sensitivity to
platinum-based drugs. First, we found that the basal
level of MVP was up-regulated in the KB/CDDP(T)
cells, compared with the parental cells, when analyzed
using immunoblot analysis (Figure 2A). Next, to con-
firm whether Vaults limited the sensitivity of CDDP in
KB/CDDP(T) cells, we assessed the effect of MVP-silencing
using RNA interference on the sensitivity to CDDP in
KB/CDDP(T) cells. Immunoblot analysis and ICC showed
that MVP-silencing sufficiently suppressed the expression
of MVP protein in KB/CDDP(T) cells (Figure 2B and C).
KB/CDDP(T) cells treated with MVP-siRNA showed a
higher sensitivity to CDDP, compared with the cells that
were treated with negative control siRNA (Figure 2D). To
further confirm this data, we assessed the effect of MVP-
silencing in A549 cells, which have a high basal level of
MVP expression, and observed a similar sensitization to
CDDP in response to MVP-silencing (Additional file 1:
Figure S2A and B). In addition, we confirmed that the
ERCC1 expression level was not different between KB/
CDDP(T) and its parental cells, since multiple studies
have shown that ERCC1 induction causes resistance to
CDDP (Additional file 1: Figure S3A). These results sug-
gest that the up-regulation of Vaults limit the sensitivity of
KB/CDDP(T) cells to CDDP.
Combination of ECyd and CDDP results in a potent
synergistic growth inhibitory effect on KB/CDDP(T)
Since we previously showed that ECyd inhibits RNA
polymerase I-III [1], we hypothesized that ECyd would
sensitize the CDDP-resistant cells by inhibiting the CDDP-
mediated induction of Vaults expression. To verify this
hypothesis, we initially assessed the combined effect of
CDDP and ECyd on cell growth. ECyd significantly
sensitized the KB/CDDP(T) cells to CDDP in a simultan-
eous 24 hours combined exposure study. An isobologram
analysis (Additional file 1: Figure S4) [33], which can dis-
tinguish between the synergistic and additive effects of
two compounds, confirmed that the combination of ECyd
and CDDP resulted in a remarkable synergistic growth in-
hibitory effect on KB/CDDP(T) (Figure 3A). In contrast,
the combined treatment exhibited an additive or moderate
synergistic effect in the parental cells (Figure 3B). These
results indicated that ECyd is more efficacious for enhan-
cing the effect of CDDP in CDDP-resistant cells with the
induced expression of MVP. In addition, we compared the
effect of the combination of CDDP and ECyd between
two ovarian cancer cell lines, SHIN-3 and HRA, with and
without high MVP expression levels, respectively. When
these cells were treated with CDDP alone, the SHIN-3
cells, which have a high MVP expression level, were less
sensitive to the drug (Figure 3C). However, in accordance
with the data for paired KB cells, the combination of
CDDP and ECyd showed a more synergistic effect on the
Figure 1 CDDP resistance shows a similar sensitivity to ECyd. A, B) Sensitivity of KB/CDDP(T) and parental cells to CDDP (A) and ECyd (B).
Data are shown as the mean (n = 4). C) The expression of UCK2 protein in KB/CDDP(T) and parental cells was also analyzed using immunoblot
analysis. Equal loading was confirmed by the detection of β-actin. D) The expression of UCK2 protein in KB/CDDP(T) and parental cells was
analyzed using immunocytochemistry with an anti-UCK2 specific antibody.
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is higher than that of the HRA cells (Figure 3D and E).
ECyd decreases vRNAs expression in tumors
In order to confirm our hypothesis that ECyd suppresses
the expression of Vaults and ECyd up-regulates the cellu-
lar sensitivity to CDDP, we assessed the MVP protein ex-
pression level after 24 hours exposure of ECyd, CDDP and
its combination. However, in contrast to our hypothesis,
24 hours exposure of ECyd, CDDP and its combination
had no effect on MVP expression levels (Figure 4A). Next,
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Cells were exposed to each drug for 72 hr. Data are shown as the mean (n = 4).vRNAs, we analyzed the expression level of vRNAs post
treatment with ECyd. Quantification of the vRNAs using
RT-PCR, which was specific for the detection of vRNAs
[34], revealed that ECyd decreased the expression levels of
vRNAs in cultured cells 2–24 hours after ECyd treatment
(Figure 4B) in vitro. We previously reported that ECyd
enhanced the anti-tumor effect of CDDP in a xenograft
tumor model in vivo [7]. Then, to address whether this
hypothesis is active in tumor cells not only in vitro but
also in vivo, we assessed the effect of CDDP and ECyd
on the expression levels of vRNAs in nude mice















































































Figure 2 Silencing of MVP increases the cellular sensitivity to CDDP. A) The basal expression of MVP protein in KB/CDDP(T) cells and parental cells
was analyzed using immunoblot analysis. B) The expression of MVP protein in KB/CDDP(T) cells treated with siRNA to MVP or negative control siRNA was
analyzed using immunoblot analysis. Equal loading was confirmed by the detection of β-actin. C) The expression of MVP protein in KB/CDDP(T) cells
treated with siRNA to MVP or negative control siRNA was analyzed using immunocytochemistry. D) The sensitivity of KB/CDDP(T) and parental cells
treated with siRNA to MVP or negative control siRNA against CDDP was analyzed. Data are shown as the mean (n = 4).
Fukushima et al. BMC Cancer 2014, 14:562 Page 6 of 12
http://www.biomedcentral.com/1471-2407/14/562the co-administration of ECyd statistically decreased
the expression levels of vRNAs in nude mice xenograft tu-
mors (Figure 4C), while no induction was observed using
CDDP alone.
ECyd suppresses the induction of MVP protein expression
in KB/CDDP(T) cells treated with CDDP
To further examine the involvement of Vaults in the
mechanism of CDDP resistance and the restoration of
the CDDP effect by ECyd, we assessed the effect of
72 hours exposure to CDDP, ECyd, and their combination
on the expression of MVP. We observed that ECyd alone
in KB/CDDP(T) decreased the protein expression of MVP
(Figure 5A), while CDDP alone significantly increased the
protein expression level of MVP in a dose-dependent
manner (Figure 5B) [35,36], although 24 hours exposure
of ECyd, CDDP and its combination had no effect on
MVP expression levels in KB/CDDP(T) cells (Figure 4A).
The exposure to CBDCA for 72 hours also inducedMVP protein in KB/CDDP(T) cells (Figure 5C), indicating
that MVP expression was generally induced by platinum
treatment in the cells. In contrast, ECyd suppressed the
CDDP-mediated induction of MVP and reversed the
protein expression levels to those similar in the control
(Figure 5D) via the inhibition of the mRNA synthesis of
MVP (Figure 5E). The CBDCA-mediated induction of
MVP expression was also reversed by ECyd treatment
(Figure 5F). These results infer that ECyd has a possibility
to enhance the anti-tumor effect of CDDP in cells by sup-
pressing the chemotherapeutics-mediated induction of the
expression of Vaults, which is the causative molecule for
platinum resistance, in addition to Vaults dysfunction by
inhibiting vRNAs synthesis.
Discussion
Although we have previously shown that ECyd enhanced
the anti-tumor effect of CDDP [7], the mechanism under-
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Figure 3 Simultaneous exposure to ECyd and CDDP causes synergistic cell growth inhibition of cells with higher MVP expression
levels. The effect of 24 hours of simultaneous exposure to ECyd and CDDP was analyzed in parental KB cells (A) and KB/CDDP(T) (B) cells. The
combined effect of ECyd with CDDP was analyzed using an isobologram analysis according to the method described by Steel and Peckham.
Data are shown as the mean (n = 4). C) The basal expression level of MVP protein in SHIN-3 and HRA cells was analyzed using immunoblot
analysis. Equal loading was confirmed by the detection of β-actin. D) The combined effect of 24 hours of simultaneous exposure to ECyd and
CDDP was analyzed in SHIN-3 (D) and HRA (E) cells. The combined effect of ECyd with CDDP was analyzed using bliss independent
combination analysis. Data are shown as the mean (n = 4).
Fukushima et al. BMC Cancer 2014, 14:562 Page 7 of 12
http://www.biomedcentral.com/1471-2407/14/562revealed that the enhancement was due to a suppressive
effect of ECyd on the Vaults complex that is up-regulated
by platinum. We carefully analyzed CDDP-resistant and
parental-paired KB cells and identified three supportive
observations demonstrating that Vaults is the causative
molecule for CDDP resistance in KB/CDDP(T) cells,
although several mechanisms of platinum-based drug
resistance have been reported [10-16]. First, CDDP
treatment induced MVP protein in a dose-dependent
manner, which was also observed by CBDCA treatment.
Second, MVP-silencing using RNA interference restored
the sensitivity to CDDP. Third, the established CDDP-
resistant cell line, KB/CDDP(T), expressed a higher MVP
expression level at baseline than its parental cell line.Other studies also reported that MVP knock-down and
treatment with anti-MVP antibody restored cellular apop-
tosis in response to CDDP exposure and increased intra-
cellular CDDP accumulation [14], supporting our finding
that the up-regulation of MVP is the major mechanism of
platinum resistance in KB/CDDP(T) cells.
The present study examined the molecular mechanism
underlying the sensitizing effect of ECyd in platinum-
resistant cells. Although we previously found that ECyd
enhances the anti-tumor effect of CDDP in both in vitro
and in vivo models [7], the molecular mechanism explain-
ing this phenomenon remained to be clarified. The strong
synergistic effect of the combination of CDDP and ECyd
in KB/CDDP(T) cells suggested an antagonistic effect of
Figure 4 ECyd decreases the expression of vRNAs, a functionally important component of Vaults. A) The expression of MVP protein in
KB/CDDP(T) cells treated with 7.0 μmol/L (IC50 value) of CDDP with or without 0.02 μmol/L ECyd (IC50 value) for 24 hours was analyzed using an
immunoblot analysis. Equal loading was documented by the detection of β-actin. B) vRNAs expression levels in KB/CDDP(T) cells treated with
0.02 μmol/L (IC50 value) of ECyd were analyzed using a modified qPCR analysis. The columns are the mean ± SD; **P < 0.01, ***P < 0.001 (n = 3). C)
vRNAs expression levels in xenograft tumors were analyzed using a modified qPCR analysis. The columns are the mean ± SD; ***P < 0.001 (n = 6).
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resulting in the efflux of CDDP. ECyd seems to exert its
suppressive effect on Vaults in two ways, since ECyd is an
inhibitor of RNA polymerase I, II, and III [37]. One mech-
anism is to suppress the expression of vRNAs via the
inhibition of RNA polymerase III [38], and the other is to
suppress the MVP protein through the inhibition of RNA
polymerase II. Especially, the finding that ECyd reduced
the expression of vRNAs, followed by the dysfunction of
Vaults, in CDDP-resistant cells is critical, since it would
allow CDDP to exert an anti-tumor effect restricted by
Vaults within 24 hours. Although ECyd alone exhibits an
anti-proliferative property in cancer cells, the observation
that the 24 hours ECyd/CDDP combination exerts a
synergistic effect strongly supports the idea that the
distorted function of Vaults contributes to the restoration
of sensitivity to CDDP, in contrast to the additive effect
of this combination in the parental KB cells. As ECydsignificantly sensitized the KB/CDDP(T) cells to CDDP
in a simultaneous 24 hours combined exposure study,
the molecular mechanisms underlying the ECyd-induced
enhancement should exert within 24 hours. Unexpectedly
24 hours exposure of ECyd, CDDP and its combination
had no effect on MVP expression levels, however, we
found that ECyd drastically decreased the expression of
vRNAs, which reportedly have the ability to play a pivotal
role in drug export, within 24 hours. Furthermore, the
decreased expression levels of vRNAs were also demon-
strated in nude mice xenograft tumor without induction
of vRNAs in CDDP alone. Therefore, we thought of the
Vaults dysfunction by the inhibition of vRNAs expression
as the mechanism underlying the ECyd-induced enhance-
ment of CDDP efficacy. In addition to Vaults dysfunction,
our additional data also indicated that 72 hours exposure
of ECyd decreased the induction of MVP expression.
Osmotic stress is known to increase the level of MVP
Figure 5 ECyd cancels the induction of MVP protein expression induced by CDDP treatment. A-C) The expression of MVP protein in KB/
CDDP(T) cells treated with 0–0.02 μmol/L (IC50 value) of ECyd (A), 0–7.0 μmol/L (IC50 value) of CDDP (B) or 0–164 μmol/L (IC50 value) of CBDCA
(C) for 72 hours was analyzed using immunoblot analysis. Equal loading was confirmed by the detection of β-actin. D) The expression of MVP
protein in KB/CDDP(T) cells treated with 0–7.0 μmol/L (IC50 value) of CDDP with or without ECyd (0.02 μmol/L) for 72 hours was analyzed using
immunoblot analysis. Equal loading was documented by the detection of β-actin. E) KB/CDDP(T) cells were treated with ECyd (0.02 μmol/L) for
several terms. The mRNA level of MVP was analyzed using RT-PCR. The Ct value of mRNA was normalized according to that of 18S rRNA as an
endogenous control. Columns, mean; bars, SD; **P < 0.01, ***P < 0.001 (n = 3). F) The expression of MVP protein in KB/CDDP(T) cells treated with
164 μmol/L (IC50 value) of CBDCA with or without ECyd (0.02 μmol/L) for 72 hours was analyzed using immunoblot analysis. Equal loading was
documented by the detection of β-actin.
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induction of MVP was observed by osmotic stress in
KB/CDDP(T) cells (Additional file 1: Figure S5A and
B). Similar to the case of the ECyd/CDDP study, ECyd
suppressed the up-regulation of MVP protein expres-
sion by osmotic stress (Additional file 1: Figure S5C),
inferring that the antagonistic effect of ECyd on MVP
up-regulation is a general observation, rather than being
specific to platinum-mediated up-regulation. Although
ECyd is an RNA polymerase inhibitor that is moderately
effective even as a single agent in cancer cells, reversing
the induction of Vaults, which renders resistance to CDDP,
might become the mechanism responsible for the synergis-
tic effect of the combined treatment in addition to Vaultsdysfunction by inhibiting the vRNAs synthesis, especially in
the long term chemotherapy which reportedly induces the
expression of Vaults [12,23,26].
Novel therapeutics to overcome CDDP resistance are
needed for the treatment of various types of cancer, such
as H&N cancer, small cell lung cancer and ovarian cancer
[10]. This study implied that ECyd and CDDP could be a
reasonable combination therapy for improving the clinical
benefit to cancer patients treated with platinum-based
therapy. Since we have shown that a synergistic anti-
tumor effect is observed in H&N cancer and ovarian can-
cer cells in the present study, similar to the effect in lung
cancer cells that we observed in our previous report [7], it
would be interesting to further investigate the effect of this
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http://www.biomedcentral.com/1471-2407/14/562combination in other types of tumors for which the stand-
ard medical care is platinum-based therapy. Furthermore,
the synergistic effect of ECyd/CDDP is expected to occur
preferentially in tumor cells, compared with normal cells.
ECyd is activated by UCK2 followed by the inhibition of
RNA polymerase I, II and III, which finally leads to the
suppression of cancer cell proliferation [6]. Although
RNA polymerases are widely expressed in various types
of cells, UCK2 is reportedly expressed at a much higher
level in tumor cells than in normal cells [6]. This finding
suggests that ECyd causes Vaults dysfunction preferen-
tially in tumor cells, minimizing side effects in the normal
cells of cancer patients treated with a combination of
ECyd and platinum. Clinical trials to determine the
maximum tolerated dose of the combination of ECyd
and carboplatin was recently completed [40]. Therefore,
the clinical outcome of these Phase II trials is eagerly
awaited.
In cancer research, the identification of biomarkers to
predict the efficacies of therapies has attracted a great
deal of attention, given the fact that the clinical benefit












Figure 6 Possible mechanism for the synergistic combination of ECyd
involved in the transport of biomolecules and drugs, and vRNAs, in particu
interactions with anticancer drugs. vRNAs is transcribed by RNA polymerase
dysfunctional Vaults that does not contain vRNAs.patients. We observed that a higher level of MVP
expression diminished the anti-tumor effect of CDDP,
and the reduction of this effect by ECyd significantly
sensitized the resistant cells. In addition to the data
indicating that ECyd restores sensitivity to CDDP, a
biological mechanism explaining this sensitization has
been revealed, in which MVP induction provides resistance
to CDDP through the down-regulation of a drug trans-
porter by ECyd. Therefore, the MVP protein level in cancer
patients could be explored as a predictive biomarker for
identifying patients who may benefit from the combination
of ECyd and platinum in future clinical trials.
Conclusion
We demonstrated the ability of ECyd to cancel the resist-
ance of cancer cells to CDDP by two mechanisms related
to the Vaults drug transporter induced by chemotherapeu-
tics, explaining the remarkable synergistic effect of CDDP
and ECyd (Figure 6). One is the Vaults dysfunction by
inhibiting the vRNAs synthesis as main mechanisms by
through of a RNA polymerase III inhibition. Another is















and CDDP through the dysfunction of Vaults. Vaults seem to be
lar, is thought to be an important component because of its
III, which is a target of ECyd, and ECyd gives rise to immature and
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http://www.biomedcentral.com/1471-2407/14/562polymerase II inhibition. These results suggest that a
clinical trial examining the combination of CDDP and
ECyd could offer a new strategy for overcoming plat-
inum resistance, which is a problem associated with
various types of cancer therapeutics, from both a basic
and clinical research perspective.
Additional file
Additional file 1: Figure S1. Structure of ECyd and mechanism by
which ECyd inhibits RNA synthesis. Figure S2. Silencing of MVP increases
the cellular sensitivity of A549 cells to CDDP. A) The sensitivity of A549
cells treated with siRNA to MVP against CDDP. Data are shown as the
mean (n = 4). B) The mRNA level of MVP in A549 cells treated with siRNA.
Figure S3. The Expression levels of ERCC1 and UCK2 are not changed. A)
The expression level of ERCC1. The effect of 72 hours exposure of ECyd (B)
and CDDP (C) to UCK2 expression. Figure S4. Schematic representation of
isobologram. The concentration of a 50% cell growth inhibition is expressed
as 1.0 on the ordinate and abscissa. The envelope of additivity, surrounded by
the mode I , mode IIa, and IIb lines, was constructed from the dose-response
curves for CDDP and ECyd. When the data point for a drug combination falls
within the envelope of additivity (P2), to the left of the envelope (P1) , to the
right of the envelope but within the square or on the square line (P3), or
outside of the square (P4), then the combination is respectively regard as
additive, supra-additive, sub-additive, or protective. Figure S5. ECyd cancels
the induction of MVP protein expression induced by treatments in KB/CDDP
(T) cells. A and B) The expression of MVP protein in KB/CDDP(T) cells treated
with sucrose for 72 hours. C) The expression of MVP protein in KB/CDDP(T)
cells treated with sucrose with or without ECyd (0.02 μmol/L) for 72 hours.
D) The expression of MVP protein in KB/CDDP(T) cells treated with ADM
for 72 hours.
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